Regen BioPharma Inc.

$RGBP $RGBPP Regen Update tomorrow will include discussing potential licensing / sale of select IP for purpose of non-dilutive funding for HemaXellerate clinical trials

$RGBP $RGBPP Regen Presenting at Emerging Growth Conference on February 25 at 3:40 - 3:50 Eastern Time. For registration goto.webcasts.com/starthere.jsp?…

$RGBP $RGBPP Regen BioPharma announces today is to the pay date for its stock dividend to shareholders of both common and preferred shares. Shareholders of record on February 3, 2026 will receive 1 share of Series A preferred stock (RGBPP) for every share of common and / or preferred stock.

$RGBP $RGBPP Regen's stock dividend record date was February 3, 2026. Pay date is February 9, 2026.

$RGBP $RGBPP Stock dividend to be paid to shareholders of record on February 3, 2026 1 share of the Company's Series A Preferred stock to be paid to both common and preferred shareholders on a one for one basis. One new share for every share owned. Pay date is set for February 9, 2026.

$RGBP $RGBPP Regen will update Series A Preferred stock dividend information at the Emerging Growth Conference January 21, 2026 (tomorrow). Time will be from 3:55 pm to 4:05 pm Eastern Time. Link is below: goto.webcasts.com/starthere.jsp?…

$RGBP $RGBPP Regen to issue stock dividend of Series A preferred stock to all shareholders of common and Series A preferred shares on a one for one basis. Details to follow.

$RGBP $RGBPP Company milestones: Regen BioPharma, Inc. milestones update regarding the Company’s recent submission of an Orphan Drug Application to the FDA for HemaXellerate as well as the Company’s planned Phase 1 clinical trial of HemaXellerate. HemaXellerate is the Company’s innovative stem cell-derived therapy which has already received FDA Investigational New Drug Application (IND) clearance. ORPHAN DRUG APPLICATION: On October 19, 2025, the Company received an acknowledgement letter from the FDA indicating preliminary comments have been addressed and informing the Company that the application will undergo FDA review which customarily takes 90 days. It cannot be determined whether or not the recent government shutdown will result in the review taking longer than 90 days. HEMAXELLERATE PHASE 1 CLINICAL TRIAL AND GOVERNMENT FUNDING APPLICATION: The Company has identified a government grant intended to fund Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases. The grant provides up to $900,000 per year for a maximum of 4 years to fund clinical trials. The Company is in the process of finalizing the budget for its planned Phase 1 clinical trial of HemaXellerate and will be applying for this grant upon finalization. The Company believes its application will be ready for submission late January2026. David Koos, the Company’s ’Chairman and CEO, expressed confidence that both Orphan Drug status for HemaXellerate and government funding for HemaXellarate’s Phase 1 Clinical trial can be obtained. “The incentives gained by being granted Orphan Drug designation for HemaXellerate would be substantial. These incentives include a tax credit equal to 25% of qualified clinical testing expenses (QCTEs) as well as up to seven years of marketing exclusivity. As far as the grant opportunity is concerned, I’ve never seen a grant more suited for a product like HemaXellerate or a product more suited for a grant. I’m confident and excited regarding these developments.” Koos went on to say that although initiation of the planned Phase 1 Clinical Trial is not exclusively contingent upon the receipt of government funding the receipt of such funding would enable the Company to apply additional internal resources toward advancing other products in development towards commercialization.

$RGBP $RGBPP Below is the link to register for the Emerging Growth conference ... Regen presents at 12 pm Eastern

$RGBP #RGBPP Regen update: 30 minute presentation at the December 10th Emerging Growth Conference. Discussions include applications for grant funding up to $950,000 for Phase I clinical trials and orphan drug status. Clinical trial status including principal investigator selection, IRB status, lab selection process, along with question and answer session.

$RGBP $RGBPP Updated research report just released on Regen BioPharma ... links to follow

$RGBP #RGBPP Regen update: 30 minute presentation at the December 10th Emerging Growth Conference. Discussions include applications for grant funding up to $950,000 for Phase I clinical trials, orphan drug status, clinical trial status, along with question and answer session. Please submit any questions or comments ASAP.

$RGBP $RGBPP Regen Biopharma, Inc. has begun the process of registering with the System for Award Management(SAM.gov), managed by the US General Services Administration, in order to access government funding for product development. Effective registration represents the first step in Regen’s plan to aggressively pursue federal funding for product development.

$RGBP $RGBPP New research report on Regen BioPharma published today

$RGBP $RGBPP Research report just released on Regen goldmansmallcapresearch.com/opportunity-re…

$RGBP $RGBPP Regen presenting at Emerging Growth Conference on Thursday ... October 23, 2025 at 4:10 pm Eastern Time. This will be an update on HemaXellerate's Orphan Drug Application, Reg A fund raising for beginning Clinical Phase I and responding to questions. Regester at: goto.webcasts.com/starthere.jsp?… Make sure to send any questions ASAP

$RGBP $RGBPP Regen BioPharma is presenting at the Emerging Growth Conference on October 23, 2025 at 4:10 pm Eastern. We will cover Orphan Drug status and HemaXellerate Clinical Phase I status. Also planning on answering questions from the audience.

$RGBP $RGBPP Goldman Small Cap Update on Regen x.com/GoldmanSmallCa…

$RGBP $RGBPP The company is currently in discussion on financing the Phase I clinical trials for HemaXellerate